Allakos (NASDAQ:ALLK) Rating Lowered to “Hold” at Citizens Jmp

Allakos (NASDAQ:ALLK) was downgraded by Citizens Jmp from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Allakos Trading Up 9.1 %

Shares of Allakos stock opened at $0.26 on Monday. The company’s 50-day moving average price is $1.04 and its two-hundred day moving average price is $0.90. Allakos has a 52 week low of $0.23 and a 52 week high of $1.69. The stock has a market cap of $23.04 million, a PE ratio of -0.13 and a beta of 0.86.

Allakos (NASDAQ:ALLK) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.01. On average, equities analysts predict that Allakos will post -1.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Point72 DIFC Ltd acquired a new position in shares of Allakos during the second quarter worth approximately $25,000. Cubist Systematic Strategies LLC acquired a new position in shares of Allakos in the second quarter valued at $55,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Allakos in the second quarter valued at $112,000. RBF Capital LLC raised its stake in shares of Allakos by 45.9% in the third quarter. RBF Capital LLC now owns 510,529 shares of the company’s stock valued at $333,000 after purchasing an additional 160,529 shares in the last quarter. Finally, GSA Capital Partners LLP raised its stake in shares of Allakos by 11.9% in the third quarter. GSA Capital Partners LLP now owns 794,896 shares of the company’s stock valued at $519,000 after purchasing an additional 84,750 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Allakos Company Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.